oxybutynin has been researched along with Disease Exacerbation in 4 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure." | 4.02 | An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021) |
| "Determine whether patients with Alzheimer's disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9." | 2.77 | Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. ( Bakchine, S; Bellelli, G; Black, SE; Caputo, A; Cummings, J; Downs, P; Froelich, L; Kressig, RW; Molinuevo, JL; Strohmaier, C, 2012) |
| "Disease progression was modelled beyond the trial period over 5 years using published equations to predict natural decline in AD patients." | 2.76 | Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. ( Akehurst, R; Brandtmüller, A; Brennan, A; Nagy, B; Sullivan, SD; Thomas, SK, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nozaki, A | 1 |
| Kobayashi, T | 1 |
| Naruhashi, K | 1 |
| Okugawa, H | 1 |
| Horiuchi, N | 1 |
| Nakanishi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, S | 1 |
| Sibiya, N | 1 |
| Mabandla, M | 1 |
| Nagy, B | 1 |
| Brennan, A | 1 |
| Brandtmüller, A | 1 |
| Thomas, SK | 1 |
| Sullivan, SD | 1 |
| Akehurst, R | 1 |
| Cummings, J | 1 |
| Froelich, L | 1 |
| Black, SE | 1 |
| Bakchine, S | 1 |
| Bellelli, G | 1 |
| Molinuevo, JL | 1 |
| Kressig, RW | 1 |
| Downs, P | 1 |
| Caputo, A | 1 |
| Strohmaier, C | 1 |
2 trials available for oxybutynin and Disease Exacerbation
| Article | Year |
|---|---|
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Topics: Alzheimer Disease; Brief Psychiatric Rating Scale; Cost-Benefit Analysis; Disease Progression; Femal | 2011 |
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2012 |
2 other studies available for oxybutynin and Disease Exacerbation
| Article | Year |
|---|---|
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago | 2021 |
The pectin-insulin patch application prevents the onset of peripheral neuropathy-like symptoms in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Hand Strength | 2018 |